Peking University Third Hospital Drug Clinical Trial Institution Participates in the 2024 DIA Conference

Author:Huang Xiaomin

https://www.puh3.net.cn/info/1971/127901.htm

From May 17 to 19, 2024, the 2024 Drug Information Association (DIA) Annual Meeting and Exhibition was held at the Suzhou International Expo Center. As part of the event, Peking University Third Hospital was invited to attend and set up a booth. Li Haiyan, Director of the Drug Clinical Trial Institution, participated in the 2024 ICH Outlook Conference plenary session and discussed the challenges and solutions for the implementation of ICH E6 (R3) in China with industry peers in related sub-forums. She also delivered an academic report titled "How to Formulate a Risk Control Plan for Oligonucleotide Drugs Based on Non-Clinical Findings." Associate Director Liu Dongyangand Chief Physician Wang Fangfang presented academic lectures in sub-forums focusing on preclinical research, translational medicine, and innovative drug development strategies, sharing relevant work experiences from Peking University Third Hospital.

Peking University Third Hospital Booth

Peking University Third Hospital Experts Delivering Presentations